Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new potency assay for the cancer vaccine Nous-209 was developed using quantitative Reverse Transcription PCR (RT-Q-PCR). This assay ensures vaccine quality by accurately measuring viral vector gene expression, crucial for clinical development.
Area Of Science
- Vaccinology
- Molecular Biology
- Cancer Therapeutics
Background
- Quality control and potency assessment are vital for vaccine clinical lot equivalence.
- Nous-209 is a novel cancer vaccine utilizing heterologous prime/boost with GAd-209 and MVA-209 viral vectors.
- Each vector encodes synthetic polypeptides comprising multiple antigenic peptide fragments.
Purpose Of The Study
- To develop and validate a potency assay for the Nous-209 cancer vaccine.
- To support the clinical advancement of Nous-209 through robust quality control.
- To enable simultaneous detection of multiple transgene transcripts.
Main Methods
- Quantitative Reverse Transcription PCR (RT-Q-PCR) was employed for potency assessment.
- The assay measures transcripts from four transgenes in each viral vector product (GAd-209 and MVA-209).
- In vitro infected cells were used to quantify transgene expression.
Main Results
- The developed RT-Q-PCR assay demonstrated robustness and biological relevance.
- The assay successfully detected potency loss in a vaccine component.
- Assay performance was comparable to in vivo immunogenicity testing.
Conclusions
- The validated potency assay is suitable for supporting the clinical development of Nous-209.
- This assay provides valuable insights for similar genetic vaccines encoding synthetic polypeptides.
- Effective quality control is essential for the successful clinical translation of novel vaccine platforms.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
